Comparative Pharmacology
Head-to-head clinical analysis: CHLOROTHIAZIDE SODIUM versus HYDROPANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROTHIAZIDE SODIUM versus HYDROPANE.
CHLOROTHIAZIDE SODIUM vs HYDROPANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in distal convoluted tubule of nephron, reducing sodium reabsorption and promoting diuresis.
Thiazide diuretic; inhibits sodium chloride cotransporter in distal convoluted tubule, increasing excretion of sodium and water, and reducing plasma volume.
500 mg to 1 g orally or intravenously once or twice daily.
50–100 mg orally once daily, maximum 200 mg daily
None Documented
None Documented
Terminal elimination half-life is 45–120 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Terminal elimination half-life is approximately 8-15 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily renal excretion via tubular secretion; approximately 95% of absorbed dose excreted unchanged in urine within 24 hours, with less than 5% eliminated via bile/feces.
Renal (approximately 50% as unchanged drug) and hepatic metabolism to inactive metabolites; fecal elimination accounts for about 10%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic